Wiedemann David, Strotmann Johanna, Fahlbusch Tim, Majchrzak-Stiller Britta, Peters Ilka, Uhl Waldemar, Höhn Philipp
Division of Molecular and Clinical Research, Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
Visc Med. 2025 Apr 4:1-9. doi: 10.1159/000545091.
Clinically relevant postoperative pancreatic fistula (CR-POPF) is a severe complication following pancreatic surgery, leading to increased mortality, morbidity, and healthcare burden. This review focuses on the role of drain amylase and lipase as biomarkers for predicting and diagnosing CR-POPF and explores perspectives considering novel markers and their clinical applicability.
A comprehensive literature review was conducted using Medline via PubMed, Scopus via Elsevier, and Web of Science via Clarivate, selecting studies from 2019 to 2024. Search terms included pancreatic fistula, drainage, amylase, lipase, biomarkers, and corresponding MeSH terms. Studies were screened and selected for their assessment of biomarker accuracy, sensitivity, specificity, and postoperative timing of drain fluid collection.
A total of 13 studies met the inclusion criteria, analyzing amylase, lipase, or other biomarkers in drain fluid for CR-POPF prediction. Both amylase and lipase consistently showed high diagnostic accuracy, with AUC values above 0.8. However, variability in optimal cut-off values across studies complicated standardization. Other drain biomarkers such as CRP or drain fluid culture positivity as well as amylase/lipase ratio and the temporal drain amylase-level progression were found to be promising predictors of CR-POPF.
Drain fluid amylase and lipase remain valuable diagnostic tools for CR-POPF, though variabilities and inconsistencies still pose challenges. Combining these with dynamic biomarker progression analysis and emerging markers as well as standardizing protocols could advance prediction and management. Further research is needed to verify the usefulness of supplementary novel biomarkers and to establish their clinical application in order to improve postoperative outcomes.
临床相关的术后胰瘘(CR-POPF)是胰腺手术后的一种严重并发症,会导致死亡率、发病率上升以及医疗负担加重。本综述聚焦于引流液淀粉酶和脂肪酶作为预测和诊断CR-POPF生物标志物的作用,并探讨考虑新型标志物及其临床适用性的观点。
通过PubMed的Medline、爱思唯尔的Scopus以及科睿唯安的Web of Science进行全面的文献综述,选取2019年至2024年的研究。检索词包括胰瘘、引流、淀粉酶、脂肪酶、生物标志物以及相应的医学主题词。筛选并选择评估生物标志物准确性、敏感性、特异性以及引流液采集术后时间的研究。
共有13项研究符合纳入标准,分析了引流液中的淀粉酶、脂肪酶或其他生物标志物以预测CR-POPF。淀粉酶和脂肪酶均始终显示出较高的诊断准确性,曲线下面积(AUC)值高于0.8。然而,各研究中最佳临界值的差异使标准化变得复杂。其他引流生物标志物,如C反应蛋白(CRP)或引流液培养阳性,以及淀粉酶/脂肪酶比值和引流液淀粉酶水平的动态变化,被发现是CR-POPF的有前景的预测指标。
引流液淀粉酶和脂肪酶仍然是CR-POPF的有价值的诊断工具,尽管变异性和不一致性仍然带来挑战。将这些与动态生物标志物变化分析、新兴标志物相结合以及标准化方案可以推进预测和管理。需要进一步研究来验证补充新型生物标志物的有用性并确立其临床应用,以改善术后结局。